Advances in Therapy

, Volume 32, Issue 1, pp 42–56 | Cite as

Current Adjuvant Therapeutic Approaches for Pancreatic Cancer

  • Fusun Ozmen
  • Tevfik Tolga Şahin
  • M. Mahir Ozmen
Review
First Online:
Received:

Abstract

Pancreatic cancer continues to be the fourth leading cause of death despite advancements in surgical and adjuvant therapeutic approaches. In the present review, the current cytotoxic therapeutic approaches and advanced targeted therapies are objectively discussed with consideration to the current literature.

Keywords

Adjuvant therapy Bevacizumab Cetuximab Chemotherapy Erlotinib Pancreatic cancer 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest

Fusun Ozmen, Tevfik Tolga Şahin, and M. Mahir Ozmen declare no conflict of interest.

Compliance with ethics guidelines

This review is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Supplementary material

12325_2015_177_MOESM1_ESM.pdf (191 kb)
Supplementary material 1 (PDF 191 kb)

References

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47(1):5–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Gaedcke J, Gunawan B, Grade M, et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg. 2010;395(4):451–8.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Balcom JH, Castillo CF. Can we predict resectability in pancreatic cancer? Ann Gastroenterol. 2000;13(3):201–6.Google Scholar
  5. 5.
    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Hackert T, Buchler M, Werner J. Current state of the surgical management of pancreatic cancer. Cancers. 2011;3:1253–73.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. Erratum in: Arch Surg 1986 Sep;121(9):1045.Google Scholar
  8. 8.
    Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Maeda A, Boku N, Fukutomi A, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol. 2008;38(3):227–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18(3):335–48.PubMedCrossRefGoogle Scholar
  14. 14.
    Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP. 2013;14(2):112–8.PubMedGoogle Scholar
  15. 15.
    Uesaka K, Fukutomi A, Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30. 2012;(suppl 34; abstr 145).Google Scholar
  16. 16.
    Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31. 2013;(suppl; abstr 4008).Google Scholar
  17. 17.
    Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99(2):108–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhang Y, Satoh K, Li M. Novel therapeutic modalities and drug delivery in pancreatic cancer – an ongoing search for improved efficacy. Drugs Context. 2012;2012:212244. doi: 10.7573/dic.212244 PubMedCentralPubMedGoogle Scholar
  19. 19.
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80(10):751–5.CrossRefGoogle Scholar
  20. 20.
    Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3(3):373–8.PubMedGoogle Scholar
  21. 21.
    Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29(31):4105–12.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.PubMedGoogle Scholar
  24. 24.
    Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007;8(16):2719–27.PubMedCrossRefGoogle Scholar
  25. 25.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.PubMedCrossRefGoogle Scholar
  26. 26.
    Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729–40.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Yu X, Zhang Y, Chen C, Yao Q, Li M. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2010;1805(1):97–104.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Berlanga-Acosta J, Gavilondo-Cowley J, Barco-Herrera DG, Martin-Machado J, Guillen-Nieto G. Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinog Mutagen. 2011;2:1.CrossRefGoogle Scholar
  29. 29.
    Einama T, Ueda S, Tsuda H, et al. Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Exp Ther Med. 2012;3(6):931–6.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol. 2003;194(1):13–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000;6(3):747–53.PubMedGoogle Scholar
  32. 32.
    Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol. 2004;54(Suppl 1):S69–77.PubMedGoogle Scholar
  33. 33.
    Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand–receptor interactions. FEBS Lett. 1997;410(1):83–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998;18(6B):4613–9.PubMedGoogle Scholar
  36. 36.
    Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13(3):565–9.PubMedGoogle Scholar
  37. 37.
    Mu DQ, Peng YS, Xu QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol. 2004;10(4):471–5.PubMedGoogle Scholar
  38. 38.
    Zhu H, Liang ZY, Ren XY, Liu TH. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Cancer Biol Ther. 2006;5(12):1693–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(3):318–30.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Peace DJ, Chen W, Nelson H, Cheever MA. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol. 1991;146(6):2059–65.PubMedGoogle Scholar
  42. 42.
    Shin SH, Kim SC, Hong SM, et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013;42(2):216–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Sirivatanauksorn V, Sirivatanauksorn Y, Lemoine NR. Molecular pattern of ductal pancreatic cancer. Langenbecks Arch Surg. 1998;383(2):105–15.PubMedCrossRefGoogle Scholar
  44. 44.
    Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266–76.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–61.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA. 2009;106(11):4254–9.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425(6960):851–6.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Wehr AY, Furth EE, Sangar V, Blair IA, Yu KH. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas. 2011;40(4):557–66.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Mahadevan D, Von Hoff DD. Tumor–stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6(4):1186–97.PubMedCrossRefGoogle Scholar
  51. 51.
    Le A, Rajeshkumar NV, Maitra A, Dang CV. Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res. 2012;18(16):4285–90.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Yang ZY, Yuan JQ, Di MY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8(3):e57528.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Li J, Saif MW. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29–June 2, 2009. JOP. 2009;10(4):361–5.PubMedGoogle Scholar
  54. 54.
    Squadroni M, Fazio N. Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 2010;14(4):386–94.PubMedGoogle Scholar
  55. 55.
    Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41(1):189–209.PubMedCrossRefGoogle Scholar
  56. 56.
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.PubMedCrossRefGoogle Scholar
  59. 59.
    Stathopoulos GP, Trafalis D, Athanasiou A, Bardi G, Chandrinou H. Serious hematologic complications following erlotinib treatment. Anticancer Res. 2010;30(3):973–6.PubMedGoogle Scholar
  60. 60.
    Faloppi L, Andrikou K, Cascinu S. Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther. 2013;13(5):791–801.PubMedCrossRefGoogle Scholar
  61. 61.
    Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6(5):1936–48.PubMedGoogle Scholar
  62. 62.
    Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP. 2007;8(1):4–15.PubMedGoogle Scholar
  63. 63.
    Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22(13):2610–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008;9(1):39–44.PubMedCrossRefGoogle Scholar
  65. 65.
    Kullmann F, Hollerbach S, Dollinger MM, et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer. 2009;100(7):1032–6.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007;18(10):1652–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605–10.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4(1):121–33.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74.PubMedCrossRefGoogle Scholar
  70. 70.
    Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19(31):5051–60.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21(6):1152–62.PubMedCrossRefGoogle Scholar
  72. 72.
    Ko AH, Youssoufian H, Gurtler J, et al. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012;30(4):1597–606.PubMedCrossRefGoogle Scholar
  73. 73.
    Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617–22.PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666–75.PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Long Y, Sun Q, Wu J, Wang Y, Jiao S. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: a case report. Oncol Lett. 2014;7(5):1594–8.PubMedCentralPubMedGoogle Scholar
  76. 76.
    Qiu Y, Yun MM, Xu MB, Wang YZ, Yun S. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol. 2013;18(4):657–65.PubMedCrossRefGoogle Scholar
  77. 77.
    Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology. 2013;2(12):e26662.Google Scholar
  78. 78.
    Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6(B):955–64.PubMedCentralPubMedGoogle Scholar
  79. 79.
    Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195–205.PubMedCrossRefGoogle Scholar
  80. 80.
    Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90(8):3539–43.PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel- L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013;17:94–100.PubMedCrossRefGoogle Scholar
  82. 82.
    Gujar SA, Lee PW. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol. 2014;4:77.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Nakao A, Kasuya H, Sahin TT, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther. 2011;18(3):167–75.PubMedCrossRefGoogle Scholar
  84. 84.
    Ishizaki H, Manuel ER, Song GY, et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2011;60(1):99–109.PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2015

Authors and Affiliations

  • Fusun Ozmen
    • 1
  • Tevfik Tolga Şahin
    • 2
  • M. Mahir Ozmen
    • 2
  1. 1.Department of Basic Oncology, Cancer InstituteHacettepe UniversityAnkaraTurkey
  2. 2.Department of Surgery, Medical SchoolHacettepe UniversityAnkaraTurkey

Personalised recommendations